Rentschler Biopharma Makes Record-Breaking Investment at German HQ
Rentschler Biopharma plans a new buffer media station in Laupheim to enhance production efficiency by 2028.
Breaking News
Oct 25, 2024
Simantini Singh Deo
Rentschler Biopharma SE, a top global contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals and advanced therapy medicinal products (ATMPs), has announced plans to build a cutting-edge buffer media station at its headquarters in Laupheim. This new facility is designed to boost production efficiency and modernize the site, enabling the company to better meet the changing demands of clients and patients now and in the future.
The new buffer media station, a modern four-story facility spanning 3,400 square metres, is scheduled to begin operations by 2028. It will be fully integrated with the current infrastructure, enhancing speed and efficiency in production. The design prioritizes ergonomics, ensuring a comfortable workspace for employees. This facility will adhere to the highest standards of quality and automation, and its advanced equipment will help Rentschler Biopharma achieve its environmental and sustainability objectives.
Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma mentioned, "This investment underscores our commitment to the long-term development of our Laupheim site, a key part of Germany’s biotechnology landscape. This expansion will strengthen our competitive position in one of the world’s fastest-growing industries. As a company with 150 years of tradition, Rentschler Biopharma has always embraced forward-looking, strategic planning, enabling us to grow sustainably as an independent family-owned company.
He further said, “I would like to thank all colleagues involved in the planning and execution of this significant project. Government support for a German national pharmaceutical strategy is an important signal for the industry as a whole. While our focus remains on strengthening global partnerships, this investment in our German site plays a crucial role in ensuring supply chain reliability and advancing our long-term growth strategy.”
Christiane Bardroff, Chief Operating Officer of Rentschler Biopharma, also added, “As a CDMO, it is our responsibility to support our clients in transforming innovative ideas into life-saving biopharmaceuticals. Patients with rare and severe diseases rely on the therapies we develop and manufacture in partnership with our clients. This project is therefore not just an investment in our infrastructure, it is a fundamental part of our work, creating value sustainably for the benefit of our clients and for patients and ensuring the availability of therapeutics in Germany and globally. With the new buffer media station, we are making a significant contribution to operational excellence, enabling us to respond rapidly to growing client demands. We are also creating a more ergonomic work environment for our employees and positioning our site for future success.”
The new facility will feature three media tanks and six buffer tanks, ensuring ample capacity for producing buffer solutions and media. To maintain optimal hygiene and safety standards, buffer and media preparation will occur in distinct areas. Additionally, the facility will integrate with the existing logistics and piping systems for upstream and downstream processes.
Planning for the new building is already underway, with construction set to begin in spring 2025. The facility is expected to be completed and operational by the end of 2027, fully operational by 2028, maximizing the capabilities of the new buffer media station.